Maple Arginine vasopressin (AVP) is a cyclic nonapeptide synthesized primarily in the hypothalamic paraventricular and supraoptic nuclei, with established roles in osmotic regulation, stress-axis modulation, and social cognition. Vasopressin peptide research has identified at least three pharmacologically distinct receptor subtypes: V1a, V1b (V3), and V2, each coupled to divergent intracellular signaling cascades and expressed in tissue-specific patterns that explain the peptide’s pleiotropic preclinical profile. For research purposes only. Not for human consumption.
Structural Biology and Synthesis
AVP (Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2; CAS 113-79-1; molecular formula C46H65N15O12S2; MW 1084.22 Da) is a disulfide-bridged nonapeptide that shares near-identical structure with oxytocin, differing only at positions 3 and 8. Phenylalanine and arginine replace isoleucine and leucine respectively. This structural similarity produces partial cross-reactivity at oxytocin receptors at supraphysiological concentrations in preclinical assays, a confound researchers must account for when designing in-vitro binding studies. The disulfide bond between Cys1 and Cys6 is essential for receptor recognition; reduced or alkylated analogs exhibit dramatically attenuated binding affinity, with Ki values shifting from low nanomolar to micromolar range across all three receptor subtypes.
Native AVP is synthesized as a larger precursor, prepropressophysin, cleaved cotranslationally to yield the mature peptide along with neurophysin II and a C-terminal glycoprotein copeptin. Copeptin has become a surrogate biomarker in clinical research because it is co-secreted in equimolar quantities with AVP but is more stable in plasma, making it technically easier to quantify in research samples. Synthetic AVP used in preclinical research is typically manufactured via solid-phase peptide synthesis (SPPS) using Fmoc chemistry, with orthogonal protection of the two cysteine residues and controlled oxidative cyclization to yield the correct disulfide regiochemistry at purity above 98% by HPLC.
Receptor Pharmacology: V1a, V1b, and V2
The V1a receptor (AVPR1A; Gq/11-coupled) is the dominant cardiovascular and hepatic subtype and the primary mediator of AVP’s vasopressor activity. V1a engagement activates phospholipase C, generating IP3 and DAG, which elevate intracellular calcium and activate protein kinase C. In vascular smooth muscle, this cascade drives vasoconstriction. Radioligand binding studies using [3H]-AVP have established V1a Ki values in the 1-3 nM range for native AVP. The receptor is also heavily expressed in the brain, particularly in the lateral septum, bed nucleus of the stria terminalis, and amygdala, placing it centrally in social behavior and affiliative circuitry.
The V1b receptor (AVPR1B; also Gq/11-coupled) is concentrated in anterior pituitary corticotrophs and limbic structures. V1b activation potentiates CRF-stimulated ACTH release from the pituitary, placing AVP as a co-secretagogue within the hypothalamic-pituitary-adrenal (HPA) axis. A pivotal 2002 study by Aguilera and colleagues published in Regulatory Peptides demonstrated that chronic stress shifts the dominant pituitary ACTH secretagogue from CRF toward AVP, with V1b receptor upregulation and CRF receptor downregulation observed across n=24 rodents subjected to 14-day repeated restraint stress, an important model for understanding stress sensitization mechanisms.
The V2 receptor (AVPR2; Gs-coupled) is the classical antidiuretic receptor, expressed predominantly in the collecting duct principal cells of the kidney. V2 activation raises intracellular cAMP via adenylyl cyclase, phosphorylates aquaporin-2 (AQP2) at Ser256, and drives AQP2 trafficking to the apical plasma membrane, increasing water reabsorption. The V2 pathway is now a well-validated research target for studying water channel biology; selective V2 antagonists (vaptans) have been used extensively in preclinical models to generate conditional states of central diabetes insipidus-like aquaporin insufficiency.
Social Memory and Affiliative Behavior
The role of AVP in social cognition is among the most intensively studied areas of neuropeptide research over the past two decades. Preclinical work using AVP receptor knockout mice has been essential in delineating which behaviors depend on V1a versus V1b signaling. A landmark study by Bielsky et al. (2004) published in Neuron showed that V1a receptor-null mice (n=18) displayed near-complete deficits in social recognition memory at a 30-minute retention interval compared to wild-type controls (p<0.001), while spatial memory in the Morris water maze remained intact, demonstrating specificity for the social domain rather than global memory impairment.
Subsequent research has focused on the lateral septum as the critical locus for V1a-mediated social memory consolidation. Microinfusion of V1a antagonists directly into the lateral septum of rats, but not into adjacent brain regions, blocks conspecific recognition at 60-minute intervals in a dose-dependent manner. Conversely, AVP microinfusion into the lateral septum of V1a knockout mice partially restores social memory at doses of 0.1-1.0 ng per site, providing direct evidence that septal V1a signaling is both necessary and partially sufficient for this cognitive function. Oxytocin receptor co-expression in lateral septal neurons further complicates receptor attribution and represents an active area of pharmacological research using subtype-selective ligands.
Research in prairie voles, a naturally monogamous rodent species that expresses unusually high V1a receptor density in the ventral pallidum, has established an influential model for studying pair bonding neurobiology. Young et al. demonstrated that species differences in the AVPR1A promoter region, specifically a microsatellite expansion upstream of the transcription start site, predict regional V1a expression patterns and correlate with affiliative behavior across vole species. This work, published in Nature (1999), was among the first to link a noncoding regulatory polymorphism to a complex social phenotype in a mammalian model, with sample sizes of n=15-22 animals per vole species group.
HPA Axis Modulation and Stress Research
AVP’s co-regulatory role in HPA axis function has generated substantial preclinical interest in V1b receptor pharmacology as a target for stress-axis research models. In the paraventricular nucleus (PVN), parvocellular neurons co-express AVP and CRF, releasing both neuropeptides into the hypophyseal portal circulation to drive ACTH secretion from anterior pituitary corticotrophs. The AVP contribution becomes proportionally dominant under chronic stress conditions, as parvocellular neurons upregulate AVP synthesis while CRF receptor internalization reduces CRF sensitivity at the pituitary.
The selective V1b antagonist SSR149415 (nelivaptan) has been used extensively in preclinical stress models to characterize the V1b-HPA pathway in isolation. A 2005 study by Griebel and colleagues in PNAS using n=10-12 Wistar rats per group demonstrated that SSR149415 significantly attenuated ACTH release in response to both pharmacological (IL-1 beta challenge, 10 mcg/kg i.v.) and psychological (forced swim) stressors, with ACTH reductions of 45-60% versus vehicle at the 30 mg/kg oral dose (p<0.01 across conditions). These findings established the V1b receptor as a functionally separable modulator of the AVP-CRF co-secretion system, with direct implications for preclinical stress model design.
AVP’s interaction with the HPA axis also extends to circadian timing. Vasopressinergic neurons in the suprachiasmatic nucleus (SCN) project to the PVN and transmit circadian timing signals to the HPA axis, creating a gate that normally suppresses ACTH release during the inactive phase. Research using AVP receptor antagonist infusions into the dorsomedial hypothalamus has shown that disruption of AVP signaling within this circuit phase-advances the daily ACTH peak by 2-4 hours in rats, independent of light entrainment, demonstrating a direct neurochemical link between the circadian oscillator and adrenocortical rhythmicity.
Cardiovascular Preclinical Evidence
V1a receptor-mediated vasoconstriction has been studied extensively in hemodynamic models. In isolated perfused rat aorta preparations, AVP produces concentration-dependent contractile responses beginning at approximately 1 pM, with EC50 values reported between 10-30 pM across multiple laboratory replication studies, making it one of the most potent endogenous vasoconstrictors studied in smooth muscle pharmacology. The vasopressor response is abolished by V1a-selective antagonists such as SR49059 (relcovaptan) at 10 nM concentrations, confirming V1a mediation rather than V2 or oxytocin receptor involvement.
In whole-animal models of hemorrhagic shock, AVP administration restores mean arterial pressure (MAP) at substantially lower doses than catecholamines, with preclinical dog studies demonstrating MAP restoration from 40 mmHg to the 80-90 mmHg target range using AVP doses of 0.04 units/kg/min intravenously (n=8 per group; Landry et al., Circulation 1997). The mechanism involves V1a-mediated arterial vasoconstriction that is preserved during catecholamine-refractory hypotension, a pharmacological property attributed to V1a receptor functionality during metabolic acidosis when adrenergic receptor signaling becomes impaired. This differential receptor sensitivity under acidotic conditions has been studied in isolated vascular ring preparations at pH 7.0 versus 7.4.
Cardiac V1a expression has been characterized in rodent and porcine myocardial preparations, where AVP stimulates hypertrophic signaling through ERK1/2 and p38 MAPK cascades. Chronic V1a receptor stimulation in neonatal rat ventricular cardiomyocyte (NRVCM) cultures at 10-100 nM AVP concentrations produces sarcomeric reorganization and beta-myosin heavy chain upregulation within 48 hours, a transcriptional signature consistent with pathological hypertrophy. These in-vitro findings have motivated research into V1a antagonism as a cardioprotective strategy in models of pressure overload, though translational significance requires intact in-vivo confirmation.
Key Research Findings
- V1a knockout mice show near-complete social recognition memory deficits at 30-minute retention intervals (p<0.001, n=18) with preserved spatial memory, demonstrating circuit-specific function (Bielsky et al., Neuron 2004).
- Selective V1b antagonist SSR149415 reduces ACTH response to psychological and pharmacological stressors by 45-60% in Wistar rats (p<0.01, n=10-12 per group; Griebel et al., PNAS 2005).
- AVP vasoconstricts isolated rat aorta preparations beginning at approximately 1 pM, with EC50 of 10-30 pM, placing it among the most potent smooth muscle constrictors characterized by vascular pharmacology.
- Prairie vole AVPR1A promoter microsatellite expansion predicts regional V1a expression density and affiliative behavior, linking regulatory genetics to a complex social phenotype (Young et al., Nature 1999).
- AVP restores MAP in canine hemorrhagic shock models at 0.04 units/kg/min via V1a vasoconstriction preserved under metabolic acidosis (Landry et al., Circulation 1997, n=8).
- V2 receptor activation phosphorylates AQP2 at Ser256, driving apical membrane trafficking and quantifiable increases in tubular water permeability in isolated collecting duct preparations.
Analytical Considerations for AVP Research
Quantification of AVP in biological matrices presents significant analytical challenges due to its low physiological concentrations (1-10 pg/mL in plasma), short half-life (approximately 20 minutes due to vasopressinase activity), and non-specific binding to glass surfaces. Standard radioimmunoassay (RIA) protocols require plasma extraction and concentration steps before AVP quantification, typically using acetone precipitation or C18 solid-phase extraction cartridges to achieve detection limits below 0.5 pg/mL. Modern LC-MS/MS methods applied to extracted plasma achieve lower quantification limits near 0.2 pg/mL with better specificity, particularly for distinguishing AVP from co-eluting matrix components in complex biological samples.
For in-vitro binding research using [3H]-AVP or fluorescently labeled AVP analogs, non-specific binding to polypropylene vessels is substantially lower than to glass, and researchers routinely add 0.1% BSA to incubation buffers to minimize surface adsorption artifacts. Batch-specific purity verification via HPLC and mass spectrometry confirmation of the correct disulfide configuration are essential quality controls before applying AVP in receptor binding or cell-based assays, as partially reduced or monomeric forms will yield artifactually low potency measurements. Third-party COA verification, such as that provided by Janoshik Analytical for Maple Research Labs products, provides the molecular weight confirmation and purity data necessary to normalize results across experimental batches.
Comparative Receptor Ligand Pharmacology
The AVP/oxytocin neuropeptide family has been extensively studied with selective pharmacological tools to dissect receptor contributions to behavior. Among the most widely used in preclinical research are: V1a-selective antagonist SR49059 (Ki = 1.0 nM at V1a vs. greater than 1000 nM at V1b and V2); V1b-selective antagonist SSR149415 (Ki = 6.0 nM at V1b vs. greater than 1000 nM at V1a and V2); and V2-selective antagonist OPC-31260 (mozavaptan; Ki = 0.43 nM at V2). These tools have enabled clean pharmacological dissection of receptor contributions in rodent behavioral batteries, though species differences in receptor pharmacology, particularly between rat and mouse V1a, complicate cross-species generalization and require species-specific validation of binding constants.
AVP differs functionally from copper-binding peptides like GHK-Cu in that its primary research utility lies in receptor pharmacology and behavioral neuroscience rather than tissue regeneration. Research groups studying the broader neuropeptide landscape increasingly use AVP alongside oxytocin as a paired experimental system to resolve social behavior circuitry, given their overlapping receptor profiles and opposing or synergistic behavioral effects depending on brain region and timing of administration.
Research Applications and Study Design Considerations
AVP is applied in three primary preclinical research contexts: behavioral neuroscience (social memory, affiliative behavior, anxiety-related phenotypes), neuroendocrinology (HPA axis regulation and stress-axis pharmacology), and cardiovascular pharmacology (vasoconstriction mechanisms and fluid balance models). Each context requires distinct study design considerations around administration route, dose-response range, and receptor selectivity confirmation. Central administration via intracerebroventricular (i.c.v.) or intra-site microinfusion is preferred for behavioral neuroscience studies to achieve pharmacologically relevant concentrations at target brain regions without systemic cardiovascular confounds from peripheral V1a activation. Peripheral administration for cardiovascular and fluid balance studies typically uses intravenous or subcutaneous routes with pharmacokinetic monitoring.
A persistent methodological challenge is the speed of AVP’s central effects versus its 20-minute plasma half-life. Studies using peripheral AVP to draw conclusions about central receptor pharmacology require rigorous controls for peripheral versus central action, including comparison groups receiving equimolar V2-selective agonists, which do not cross the blood-brain barrier under normal conditions, to attribute behavioral effects specifically to central receptors. For groups working with lyophilized AVP, the reconstitution and storage protocols described in Maple Research Labs documentation apply, particularly the use of 0.1% acetic acid as reconstitution solvent to maintain peptide integrity and prevent aggregation at concentrations above 1 mg/mL.
Researchers accessing AVP for pharmacological study should verify batch-specific purity against a third-party certificate of analysis confirming HPLC purity, correct molecular weight by mass spectrometry, and absence of significant truncation or oxidation byproducts. Given AVP’s disulfide bond, oxidative status directly impacts receptor binding activity, and COA data should include confirmation of intact cyclic structure rather than linear reduced analog contamination. View our full research peptide catalog for available compounds and batch documentation.
For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.
Want more research like this?
Weekly peptide study breakdowns. No spam. Unsubscribe anytime.